239,749 Shares in Vaxcyte, Inc. $PCVX Acquired by University of Wisconsin Foundation

University of Wisconsin Foundation bought a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 239,749 shares of the company’s stock, valued at approximately $13,937,000. Vaxcyte comprises 11.0% of University of Wisconsin Foundation’s holdings, making the stock its 4th largest holding. University of Wisconsin Foundation owned about 0.16% of Vaxcyte as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of PCVX. NEXTBio Capital Management LP bought a new position in Vaxcyte in the fourth quarter valued at about $4,406,000. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in shares of Vaxcyte by 105.3% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 70,124 shares of the company’s stock valued at $3,236,000 after purchasing an additional 35,974 shares during the period. Norges Bank bought a new stake in shares of Vaxcyte during the 4th quarter valued at about $56,703,000. Bank of America Corp DE increased its position in shares of Vaxcyte by 73.4% during the 1st quarter. Bank of America Corp DE now owns 1,216,843 shares of the company’s stock valued at $70,711,000 after purchasing an additional 515,209 shares during the last quarter. Finally, Candriam S.C.A. purchased a new stake in shares of Vaxcyte during the 1st quarter valued at about $18,306,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Harpreet S. Dhaliwal sold 17,000 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total value of $935,000.00. Following the completion of the sale, the insider directly owned 76,756 shares of the company’s stock, valued at $4,221,580. This represents a 18.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the firm’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $57.28, for a total transaction of $572,800.00. Following the sale, the chief financial officer owned 104,395 shares in the company, valued at $5,979,745.60. The trade was a 8.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 120,646 shares of company stock valued at $6,570,810. Insiders own 3.30% of the company’s stock.

Vaxcyte Stock Performance

NASDAQ PCVX opened at $61.87 on Tuesday. The business’s fifty day moving average is $56.67 and its 200 day moving average is $55.84. Vaxcyte, Inc. has a fifty-two week low of $29.87 and a fifty-two week high of $65.00. The company has a market capitalization of $9.21 billion, a PE ratio of -8.11 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.09. During the same period in the previous year, the firm posted ($1.22) earnings per share. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -7.6 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on PCVX shares. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $86.00.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.